LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Celldex’s promising clinical trial results and future prospects. The company recently announced positive 20-week results from a Phase 2 trial of barzolvolimab for chronic inducible urticaria, which were consistent with earlier 12-week findings. This consistency in efficacy, coupled with the best overall efficacy data in both chronic spontaneous urticaria and chronic inducible urticaria from randomized trials, supports the potential of barzolvolimab as a leading treatment option.
Additionally, the safety profile of barzolvolimab remains favorable, with adverse events being mostly mild and reversible. The upcoming Phase 3 study planned for December 2025 further enhances the company’s outlook, as there are currently no approved therapies for chronic inducible urticaria. Celldex’s financial position, with approximately 2.5 years of cash runway, also adds to the confidence in its ability to advance its clinical programs.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.